Substance Use in Pregnancy

Substance exposure in pregnancy is both a maternal medication-safety issue and a fetal–newborn health issue. The nurse must reduce harmful exposure without creating a second danger through untreated withdrawal, overdose, or interruption of effective therapy. Risk is not binary. The substance, amount, frequency, timing, route, co-exposures, and the pregnant person's overall health all affect the clinical picture. A disclosure therefore calls for focused assessment and coordinated support—not assumptions about the parent or fetus. The central medication distinction is this: opioid use disorder is treated with opioid agonist therapy during pregnancy, whereas alcohol, cannabis, tobacco, vaping, and stimulant exposure require cessation counselling and appropriate referral. A newborn may still develop opioid withdrawal despite appropriate maternal treatment; that predictable possibility is monitored and treated rather than used as a reason to stop therapy.